Amicus Therapeutics, Inc. (FOLD)
-NasdaqGM 3.46 
0.00(0.07%) 11:23AM EDT - Nasdaq Real Time Price
| Prev Close: | 3.46 |
|---|
| Open: | 3.44 |
|---|
| Bid: | 3.44 x 200 |
|---|
| Ask: | 3.45 x 1500 |
|---|
| 1y Target Est: | 4.70 |
|---|
| Beta: | 1.83 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 3.32 - 3.47 |
|---|
| 52wk Range: | 2.47 - 6.89 |
|---|
| Volume: | 80,491 |
|---|
| Avg Vol (3m): | 496,556 |
|---|
| Market Cap: | 171.60M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.10 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhiEDGAR Online(Wed, May 22)
- Amicus Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Tue, May 21)
- AMICUS THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Amicus Therapeutics: The Good And The Badat Seeking Alpha(Wed, May 15)
- Amicus Therapeutics to Present at UBS Global Healthcare ConferenceGlobeNewswire(Tue, May 14)
- Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmedat Seeking Alpha(Tue, May 14)
- Amicus' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 10)
- Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate UpdatesGlobeNewswire(Thu, May 9)
- AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Thu, May 9)
- Q1 2013 Amicus Therapeutics, Inc. Earnings Release - After Market CloseCCBN(Thu, May 9)
- Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013GlobeNewswire(Thu, May 2)
- [$$] Previewat Barrons.com(Sat, Apr 27)
- Amicus Therapeutics to Present at 12th Annual Needham Healthcare ConferenceGlobeNewswire(Wed, Apr 24)
- AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibEDGAR Online(Wed, Apr 24)
- Curing Parkinson's: The Alternative Approach - Is There Money To Be Made?at Seeking Alpha(Thu, Apr 4)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 16.14 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.41 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.35 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones.
View More